Holen Sie sich die Stockscreener-App
6.008
1.67%
-0.092
Schlusskurs vom Vortag:
$6.10
Offen:
$6.08
24-Stunden-Volumen:
199.54K
Relative Volume:
0.39
Marktkapitalisierung:
$469.15M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-158.35M
KGV:
-3.0774
EPS:
-1.9523
Netto-Cashflow:
$-132.03M
1W Leistung:
+1.84%
1M Leistung:
+39.17%
6M Leistung:
+91.02%
1J Leistung:
+96.02%
1-Tages-Spanne:
$5.98
$6.14
1-Wochen-Bereich:
$5.755
$6.45
52-Wochen-Spanne:
$2.455
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 284-8891
Adresse
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
6.005 | 476.57M | 351.37M | -158.35M | -132.03M | -1.9523 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month HighHere's Why - MarketBeat
Atea Pharma presents data on compounds for hepatitis E - BioWorld MedTech
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI - GuruFocus
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript - Insider Monkey
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - AOL.com
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026 - TipRanks
Can Atea Pharmaceuticals Inc stock double in the next year2025 Winners & Losers & Consistent Income Trade Ideas - baoquankhu1.vn
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
AVIR: Phase III HCV trials near completion, HEV pipeline expanded, and cash runway extends through 2027 - TradingView
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss - Investing.com
AVIR: Phase 3 HCV trials near completion, with robust cash and new HEV candidate advancing - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - Benzinga
Risk Off: Can Atea Pharmaceuticals Inc navigate macro headwinds2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
AVIR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - The Manila Times
Atea Pharmaceuticals to Host Fourth Quarter and Full Year - GlobeNewswire
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - Defense World
AVIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atea Pharmaceuticals presents preclinical results of AT-587 - marketscreener.com
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - GlobeNewswire
No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR - Defense World
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - AOL.com
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
Is Atea Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Published on: 2026-02-08 21:54:48 - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2%Time to Sell? - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% – Here’s What Happened - Defense World
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26% - AOL.com
Street Watch: Is Atea Pharmaceuticals Inc attractive for institutional investorsIndex Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug Closing: Is Atea Pharmaceuticals Inc still a buy after recent gains2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Sectors: Will BIIB benefit from sector rotationJuly 2025 Final Week & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Atea Pharmaceuticals Inc. face regulatory challengesDividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
Risk Hedge: Can Atea Pharmaceuticals Inc stock double in the next yearJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Update Report: Is Atea Pharmaceuticals Inc stock undervalued right now2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug EndMonth: Can The AZEK Company Inc stock double in the next yearJuly 2025 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atea Pharmaceuticals Inc-Aktie (AVIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Murphy Polly A. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
86,045 |
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):